Medivir, Interim Report, 1 January - 30 September 2005

Huddinge, SWEDEN


HUDDINGE, Sweden, Oct. 26, 2005 (PRIMEZONE) -- Medivir, Interim Report, 1 January -- 30 September 2005

-- A phase IIa study on MIV-210 against multiresistant HIV began in September.

-- A Candidate drug (CD) was designated on the Cathepsin K project against osteoporosis in May.

-- BI (Boehringer Ingelheim) concluded its research collaboration with Medivir on the HIV compound MIV-310 (polymerase inhibitor) in March. Medivir has decided to prioritize its protease projects, and accordingly, will not assign in-house resources to MIV-310 until further notice.

-- Consolidated net sales were SEK 41.0 (18.4) m in the period.

-- The loss after tax was SEK -112.6 (-132.3) m; earnings per share were SEK -8.72 (-12.31).

FOR MORE INFORMATION, PLEASE CONTACT Rein Piir, CFO and VP, Investor Relations: +46 (0)70 853 7292.

FORTHCOMING FINANCIAL INFORMATION

The Financial Statement will be published on 16 February 2006 The Three-month Interim Report will be published on 26 April 2006 The Annual General Meeting will be on 26 April 2006, from 3 p.m.

Medivir's financial reports are available from its Website, www.medivir.se from these dates.

The Medivir Group Medivir is an innovative, specialist research company that develops drugs with the objective of becoming a sustaining, profitable pharmaceuticals company. Medivir is located in Huddinge, Sweden and at Chesterford Research Park, Essex, UK.

Medivir's research is oriented on developing new drug compounds based on polymerases and proteases as target enzymes. The group consists of Medivir AB, its subsidiary Medivir UK Ltd. and Medivir Personal AB. As of 30 September 2005, the group had 129 employees. Medivir was listed on the Stockholm Exchange O-list in 1996.

Medivir's research portfolio includes projects against HIV, jaundice, shingles, cold sores, osteoporosis, RA (rheumatoid arthritis), asthma and MS (multiple sclerosis). Medivir has five projects in clinical development phases, each with a unique clinical profile. The company's broad-based preclinical research portfolio houses six defined projects and nearly ten activities in various preclinical phases.

Medivir AB (publ), Lunastigen 7, 141 44 Huddinge, Sweden, tel (switchboard): +46 (0)8 546 83100

This information was brought to you by Waymaker.

http://www.waymaker.net

The following files are available for download:

http://wpy.waymaker.net/client/waymaker1/WOLReleaseFile.aspx?id=144917&fn=wkr0001.pdf